Trial Condition(s):
Hypogonadism
Association between the Prevalence of cardiovascular risk factors and new use of testosterone
Bayer Identifier:
19547
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
We will investigate if testosterone is preferentially given to patients at higher risk of cardiovascular events. If this is the case, then observational studies may be prone to selection bias resulting in overestimation of the cardiovascular risk associated with testosterone when compared to a healthier population not taking testosterone
Inclusion Criteria
- All male individuals in the source population with a first testosterone use during the study period will be included as cases. The date of the GP consultation associated with the first testosterone prescription will be designated as the index day.
Exclusion Criteria
- Patients of less than 18 years on the index day, with less than 2-year contribution to the CPRD-HES link before the index day, or with use of testosterone before the study period will be excluded from the group of cases.
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Many Locations Berlin, Germany, 13342 | Contact Us: E-mail: [email protected] Phone: (+) 1-888-8422937 |
Trial Design
Association between the prevalence of cardiovascular risk factors and new use of testosterone
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
2
Primary Outcome
- Estimation of the association between cardiovascular risk factors and initiation of testosterone therapyTimeframe: Retrospectively from 01 January 2001 to 31 March 2016
Additional Information
Copyright © Bayer
Powered by
